DXNVX Selected for National Project to Develop Adult Disease Diagnostic Sensor

DXVX announced on the 7th that it has been selected for the national project “K-Sensor Technology Development Led by Korea for Market Leadership,” supported by the Ministry of Trade, Industry and Energy and managed by the Korea Institute for Advancement of Technology (KIAT).

The development project is titled “Development of an Optical Sensor System for Early Diagnosis of Adult Diseases Based on Biomarkers in Urine.” It aims to discover biomarkers in urine (such as volatile organic compounds, glucose, and other biochemical substances) for continuous monitoring and early diagnosis of various adult diseases including diabetes and prostate cancer. The project involves developing an ex vivo POCT (point-of-care testing) device capable of measuring various secured biomarkers by applying MEMS (micro-electromechanical systems) technology, optical technology, semiconductor technology for signal processing, and artificial intelligence analysis technology.

With a budget of approximately 4.68 billion KRW over three years (3.7 billion KRW government funding), DXVX will lead the development as the consortium’s lead company. The project will be jointly developed with the Korea Electronics Technology Institute (KETI), Hanyang University College of Medicine’s Department of Urology, and Korea University’s Department of Electrical and Electronic Engineering, with Kori Group participating as a demand company.

DXVX expects to accelerate its total bio healthcare solution business through this project selection. In particular, after product development, it plans to launch locally in China through its Chinese subsidiary and conduct global sales via Kori Group’s overseas network, anticipating increased sales and growth in the ex vivo diagnostic business.

A DXVX representative stated, “Starting with the diagnostic development business that fuses bio and semiconductor technologies, we will expand additional module development using AI and IoT technologies, data analysis algorithms, and early diagnosis technology development. We aim to address unmet needs in bio healthcare and early diagnosis of various adult diseases amid the global aging trend by providing total healthcare solutions utilizing ultra-small system semiconductors for diagnosis and treatment management.”

The products to be developed in the future are expected to be applicable to various adult diseases such as diabetes, hypertension, prostate cancer, and bladder cancer. They will be introduced as a product line of non-invasive POCT devices and cartridges for early diagnosis of adult diseases, designed with user convenience in mind.